The DOI matches its Crossref record.
Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma
Abstract
In a prospective phase I/II clinical study, we treated eight patients suffering from recurrent glioblastoma multiform with stereotactically guided intratumoral convection‐enhanced delivery of an HSV‐1‐tk gene–bearing liposomal vector and systemic ganciclovir. Noninvasive identification of target tissue together with assessment of vector‐distribution volume and the effects of gene therapy were achieved using magnetic resonance imaging and positron emission tomography. The treatment was tolerated well without major side effects. In two of eight patients, we observed a greater than 50% reduction of tumor volume and in six of eight patients focal treatment effects. Intracerebral infusion of contrast medium before vector application displayed substantial inhomogeneity of tissue staining indicating the need of test infusions to monitor the mechanical distribution of vectors. Visualization of therapeutic effects on tumor metabolism and documentation of gene expression using positron emission tomography indicated that molecular imaging technology appears to be essential for the further development of biological treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
“CED in humans with glioblastoma multiform causes a preferential flow of the forced fluid along white matter tracts.(19) CED in the adult Rhesus monkey brain with glial-derived neurotrophic factor involved the infusion of relatively small volumes of 0.”
BackgroundNonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Kievit, F. M., & Zhang, M. (2011) · Advanced Materials · doi:10.1002/adma.201102313 · Cited by 496
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
Kunwar, S., Chang, S., Westphal, M., Vogelbaum, M., Sampson, J., Barnett, G., Shaffrey, M., Ram, Z., Piepmeier, J., Prados, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop054 · Cited by 483
Aryal, M., Arvanitis, C. D., Alexander, P. M., & McDannold, N. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.008 · Cited by 443
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
“particles [205, 206], oligonucleotides [207, 208], and gene therapies [202, 205, 206].”
BackgroundHadjipanayis, C. G., Machaidze, R., Kaluzova, M., Wang, L., Schuette, A. J., Chen, H., Wu, X., & Mao, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1022 · Cited by 419
Current approaches of nanomedicines in the market and various stage of clinical translation
Shan, X., Gong, X., Li, J., Wen, J., Li, Y., & Zhang, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.025 · Cited by 335
Mehta, A. M., Sonabend, A. M., & Bruce, J. N. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0520-4 · Cited by 331
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 307
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors
Allard, E., Passirani, C., & Benoit, J.-P. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.003 · Cited by 294
Cationic liposomes for gene delivery
Simões, S., Filipe, A., Faneca, H., Mano, M., Penacho, N., Düzgünes, N., & Pedroso de Lima, M. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.2.237 · Cited by 285
Souweidane, M. M., Kramer, K., Pandit-Taskar, N., Zhou, Z., Haque, S., Zanzonico, P., Carrasquillo, J. A., Lyashchenko, S. K., Thakur, S. B., Donzelli, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30322-x · Cited by 267
Molecular Trojan horses for blood–brain barrier drug delivery
PARDRIDGE, W. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.06.001 · Cited by 260
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Chaichana, K. L., Pinheiro, L., & Brem, H. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.114 · Cited by 91
Highly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the Brain
Mastorakos, P., Zhang, C., Berry, S., Oh, Y., Lee, S., Eberhart, C. G., Woodworth, G. F., Suk, J. S., & Hanes, J. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400800 · Cited by 80
Taoka, T., Ito, R., Nakamichi, R., Nakane, T., & Naganawa, S. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-026-02035-0 · Cited by 22
Metadata
- Authors
- Voges, J., Reszka, R., Gossmann, A., Dittmar, C., Richter, R., Garlip, G., Kracht, L., Coenen, H. H., Sturm, V., Wienhard, K., Heiss, W., & Jacobs, A. H.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2003-09-11
- Volume
- 54
- Issue
- 4
- Pages
- 479-487
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2016044792
- Cited by
- 250
- References
- 0
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.